Research programme: tubulin polymerisation inhibitors - Abbott

Drug Profile

Research programme: tubulin polymerisation inhibitors - Abbott

Alternative Names: A 353476; A-318484; A-318492

Latest Information Update: 24 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Class Hydrazones
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 09 Sep 2004 Data presented at the 228th American Chemical Society National Meeting - (228th-ACS-2004) have been added to the Cancer pharmacodynamics section
  • 30 Apr 2002 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top